Premium
Antiamnesic activity of the nicotinic agonist DBO‐83 in mice
Author(s) -
Ghelardini Carla,
Galeotti Nicoletta,
Giuliani Francesco,
Barlocco Daniela,
Bartolini Alessandro
Publication year - 1998
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/(sici)1098-2299(199810)45:2<45::aid-ddr1>3.0.co;2-q
Subject(s) - piracetam , physostigmine , pharmacology , mecamylamine , agonist , nootropic , licking , amnesia , chemistry , medicine , antagonist , acetylcholine , receptor , psychiatry
The effect of administration of DBO‐83 on memory processes was evaluated in the mouse passive avoidance test. DBO‐83 (1–5 mgkg –1 ip) prevented amnesia induced by scopolamine (1.5 mgkg –1 ip), mecamylamine (20 mgkg –1 ip) and dihydro‐β‐erythroidine (10 μg per mouse i.c.v.). In the same experimental conditions, DBO‐83 (10 mgkg –1 ip) also prevented baclofen (2 mgkg –1 ip), clonidine (0.125 mgkg –1 ip) and diphenhydramine (20 mgkg –1 ip) amnesia in mice. The antiamnesic effect of DBO‐83 was comparable to that exerted by nicotine (2 mgkg –1 ip), physostigmine (0.2 mgkg –1 ip), and the nootropic drug, piracetam (30 mgkg –1 ip). In the antiamnesic dose‐range, DBO‐83 did not impair mouse motor coordination and spontaneous motility, as revealed, respectively, by the Animex apparatus and rotarod test. These results demonstrated the ability of DBO‐83 to modulate memory functions and suggest that DBO‐83 could be useful in the treatment of cognitive deficits. Drug Dev. Res. 45:45–51, 1998. © 1998 Wiley‐Liss, Inc.